The University of Colorado Cancer Center (UCCC) is the only NCI-designated comprehensive Cancer Center in the Rocky Mountain region - an area with a population of approximately eight million people. The goals are to reduce the cancer burden by: 1) conducting coordinated and interdisciplinary basic, clinical, translation, prevention and control, population, and educational research, 2) providing citizens of Colorado and the Rocky Mountain region with state-of-the art programs in cancer research, therapy, early detection, prevention and control, and 3) providing cancer education at all levels from students to the public sector. There are 271 full and 110 associate members who participate in one or more of the UCCC's eight programs including Cancer Cell Biology, Molecular and Structural Biology, Immunology and Immunotherapy, Hormone Related Malignancies, Tobacco Related Malignancies, Developmental Therapeutics, Carcinogenesis and Chemoprevention, and Clinical and Community Cancer Prevention and Control. Over the past five years, the NCI sponsored research portfolio has nearly doubled from $21 million to $39.7 million, excluding the CCSG. This was accomplished largely through the successful funding of major new collaborative NCI grants and contracts totaling more than $7 million annually and through the recruitment of 100 new members who hold more than $14 million in NCI grant support. Over the past five years, the number of subjects accrued to clinical trials and the number of outpatient visits have also doubled. The Cancer Center is a """"""""matrix"""""""" Cancer Center within the University of Colorado Denver and Health Sciences Center and we are applying as a consortium with members from the University of Colorado at Boulder campus, the AMC Cancer Research Center, the National Jewish Medical and Research Center, and the Colorado State University campuses. These consortium members strengthen and broaden cancer research activities. Member research is supported by 15 shared core resources, of which the Informatics shared resource and the Structural Biology shared resource are new. Major new services and equipment were added to most of the shared resources. Center members also benefit from the Development activities of the Cancer Center that bring new recruitments, pilot projects and shared facilities. Planning and evaluation efforts have allowed our on-going move to the new Fitzsimons campus to provide state-of-the art facilities and increased collaborations. The completion of the new campus will allow continued growth over the next five years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046934-21S2
Application #
7683520
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ogunbiyi, Peter
Project Start
1997-04-04
Project End
2011-01-31
Budget Start
2008-08-01
Budget End
2009-01-31
Support Year
21
Fiscal Year
2008
Total Cost
$73,150
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Tuttle, Kathryn D; Krovi, S Harsha; Zhang, Jingjing et al. (2018) TCR signal strength controls thymic differentiation of iNKT cell subsets. Nat Commun 9:2650
Keysar, Stephen B; Eagles, Justin R; Miller, Bettina et al. (2018) Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. Clin Cancer Res 24:2935-2943
Salmon, Loïc; Stull, Frederick; Sayle, Sabrina et al. (2018) The Mechanism of HdeA Unfolding and Chaperone Activation. J Mol Biol 430:33-40
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60
Steckelberg, Anna-Lena; Akiyama, Benjamin M; Costantino, David A et al. (2018) A folded viral noncoding RNA blocks host cell exoribonucleases through a conformationally dynamic RNA structure. Proc Natl Acad Sci U S A 115:6404-6409
Pilling, Amanda B; Kim, Jihye; Estrada-Bernal, Adriana et al. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget 9:8823-8835
Antonioli, Alexandra H; White, Janice; Crawford, Frances et al. (2018) Modulation of the Alternative Pathway of Complement by Murine Factor H-Related Proteins. J Immunol 200:316-326
Boswell, Zachary K; Rahman, Samiur; Canny, Marella D et al. (2018) A dynamic allosteric pathway underlies Rad50 ABC ATPase function in DNA repair. Sci Rep 8:1639
Fitzwalter, Brent E; Towers, Christina G; Sullivan, Kelly D et al. (2018) Autophagy Inhibition Mediates Apoptosis Sensitization in Cancer Therapy by Relieving FOXO3a Turnover. Dev Cell 44:555-565.e3
Duex, Jason E; Swain, Kalin E; Dancik, Garrett M et al. (2018) Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer. Mol Cancer Res 16:69-77

Showing the most recent 10 out of 1634 publications